BiotechTube

MET097 + Placebo

Phase 3Recruiting
0 views this week 0 watching⚡ Active💉Featured in GLP-1 & Metabolic Watch
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Obesity and Overweight

Conditions

Obesity and Overweight

Trial Timeline

Dec 29, 2025 → May 1, 2028

NCT ID
NCT07311850

About MET097 + Placebo

MET097 + Placebo is a phase 3 stage product being developed by Pfizer for Obesity and Overweight. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07311850. Target conditions include Obesity and Overweight.

What happened to similar drugs?

20 of 20 similar drugs in Obesity and Overweight were approved

Approved (20) Terminated (5) Active (0)
✅exenatide + PlaceboEli LillyApproved
✅TirzepatideEli LillyApproved
✅Micafungin + MicafunginAstellas PharmaApproved
✅MicafunginAstellas PharmaApproved
✅Zonegran + PlaceboEisaiApproved
✅lorcaserin hydrochloride XR + PlaceboEisaiApproved
✅Placebo + TirzepatideEli LillyApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT07311850Phase 3Recruiting
NCT06973720Phase 2Active
NCT06712836Phase 2Active

Competing Products

20 competing products in Obesity and Overweight

See all competitors
ProductCompanyStageHype Score
MK0493MerckPhase 2
35
MK0557MerckPhase 3
40
AMG 786AmgenPhase 1
29
Bimagrumab + Tirzepatide + Bimagrumab Placebo + Tirzepatide PlaceboEli LillyPhase 2
39
TirzepatideEli LillyPhase 2
42
exenatide + PlaceboEli LillyApproved
43
BrenipatideEli LillyPhase 1
36
Orforglipron + PlaceboEli LillyPhase 3
47
TERN-601Terns PharmaceuticalsPhase 2
32
MBX 4291 + PlaceboMBX BiosciencesPhase 1
30
PG-102Rani TherapeuticsPhase 1
26
Orforglipron + PlaceboEli LillyPhase 1
29
Tirzepatide + PlaceboEli LillyPhase 3
40
Eloralintide + PlaceboEli LillyPhase 1
29
Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide PlaceboEli LillyPhase 2
27
LY3437943 + Midazolam + Warfarin + CaffeineEli LillyPhase 1
29
Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injectionSkye BiosciencePhase 2
29
TirzepatideEli LillyApproved
50
Adenosine + RegadenosonAstellas PharmaPre-clinical
26
Micafungin + MicafunginAstellas PharmaApproved
43